Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist

Advances in Therapy

Volumn 26, Issue 2, 2009, Pages 230-240

  Denker, Andrew E ^a   Morelli, Gaetano ^b   Vessey, Laura K ^c   Li, Susie ^c   Yuan, Jinyu ^c,d   Dunbar, Stephanie ^c,e   Lewis, Nicole M ^c   Taggart, William ^c   Wagner, John A ^c  

^a Merck Research Laboratories Boston   (United States)

^b MDS Inc   (Canada)

^c MERCK RESEARCH LABORATORIES   (United States)

^d PFIZER INC   (United States)

^e Teva LLC   (United States)

Author keywords

Cannabinoid 1 receptor inverse agonist; CB1R; Digoxin; Pharmacokinetics; Taranabant

Indexed keywords

DIGOXIN; TARANABANT;

ADULT; ANOREXIA; APPETITE; AREA UNDER THE CURVE; ARTICLE; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEMALE; HUMAN; IMMUNOREACTIVITY; INSOMNIA; LEUKOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OPEN STUDY; PHARMACODYNAMICS; PHARMACOKINETICS; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER ABDOMINAL PAIN; VOMITING;

ADMINISTRATION, ORAL; ADULT; AMIDES; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CARDIOTONIC AGENTS; DIGOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HALF-LIFE; HUMANS; LEAST-SQUARES ANALYSIS; LINEAR MODELS; MALE; MIDDLE AGED; PYRIDINES; SAFETY; WEIGHT LOSS;

EID: 73449115675     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0003-z     Document Type: Article

References (22)

1. S. Snel J.A. Jansen P.C. Pedersen J.H. Jonkman P.N. van Heiningen 1998 Tiagabine, a novel antiepileptic agent: lack of pharmacokinetic interaction with digoxin Eur J Clin Pharmacol 54 355 357 9696964 10.1007/s002280050474 1:CAS:528:DyaK1cXktFKlsLg%3D (Pubitemid 28328024)
2. Reuning RH, Geraets DR. Digoxin. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutics Drug Monitoring. 2nd edition. Spokane, WA: Applied Therapeutics Inc; 1986:570-623.
3. W.M. Awni Z. Hussein J.H. Cavanaugh G.R. Granneman L.M. Dube 1995 Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans Clin Pharmacokinet 29 suppl.2 92 97 8620677 10.2165/00003088-199500292- 00013 1:CAS:528:DyaK28XnsVSntA%3D%3D
4. S. Harder P.A. Thurmann 1997 Pharmacokinetic and pharmacodynamic interaction trial after repeated oral doses of imidapril and digoxin in healthy volunteers Br J Clin Pharmacol 43 475 480 9159562 10.1046/j.1365-2125.1997. 00588.x 1:CAS:528:DyaK2sXjs1ChsLk%3D
5. World Health Organization. Obesity fact sheet No. 311. Available at: www.who.int/mediacentre/factsheets/fs311/en/index.html. Accessed January 1, 2009.
6. National Institutes of Health. 1998 Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report Obes Res 6 suppl2. 51 209
7. L.A. Matsuda S.J. Lolait M.J. Brownstein A.C. Young T.I. Bonner 1990 Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 561 564 2165569 10.1038/346561a0 1:CAS:528:DyaK3cXls1Ghu7w%3D (Pubitemid 20238806)
8. A.C. Howlett 2002 The cannabinoid receptors Prostaglandins Other Lipid Mediat 68-69 619 631 12432948 10.1016/S0090-6980(02)00060-6 (Pubitemid 35247425)
9. T.C. Kirkham S.A. Tucci 2006 Endocannabinoids in appetite control and the treatment of obesity CNS Neurol Disord Drug Targets 5 272 292 16787229 10.2174/187152706777452272 1:STN:280:DC%2BD28znt1ShtQ%3D%3D
10. T.C. Kirkham 2003 Endogenous cannabinoids: a new target in the treatment of obesity Am J Physiol Regul Integr Comp Physiol 284 R343 R344 12529283 1:CAS:528:DC%2BD3sXhtlOqsb8%3D
11. C. Addy H. Wright K,. T. Van Laere 2008 he acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake Cell Metab 7 68 78 18177726 10.1016/j.cmet.2007.11.012 1:CAS:528:DC%2BD1cXnsFSntw%3D%3D
12. L.S. Lin T.J. Lanza Jr. J.P. Jewell 2006 Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl) pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity J Med Chem 49 7584 7587 17181138 10.1021/jm060996+ 1:CAS:528:DC%2BD28XhtlCqsLvK (Pubitemid 46033647)
13. T.M. Fong X.M. Guan D.J. Marsh 2007 Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3- cyanophenyl)-1-methylpropyl]-2-methyl-2 -[[5-(trifluoromethyl)pyridin-2-yl]oxy] propanamide (MK-0364), in rodents J Pharmacol Exp Ther 321 1013 1022 17327489 10.1124/jpet.106.118737 1:CAS:528:DC%2BD2sXmsFeqsrY%3D (Pubitemid 46762708)
14. I. Gantz N. Erondu S. Suryawanshi 2008 A two year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results J Am Coll Cardiol 1 A326
15. K.M. Williamson K.A. Thrasher K.B. Fulton 1998 Digoxin toxicity: an evaluation in current clinical practice Arch Intern Med 158 2444 2449 9855382 10.1001/archinte.158.22.2444 1:CAS:528:DyaK1MXhsFSmug%3D%3D
16. T. Theibaut T. Tsuruo H. Hamada M.M. Gottesman I. Pastan M.C. Willinghan 1987 Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc Natl Acad Sci U S A 84 7735 7738 10.1073/pnas.84.21.7735
17. J.I. Schwartz M. De Smet P.J. Larson 2001 Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers J Clin Pharmacol 41 107 112 11144988 1:CAS:528:DC%2BD3MXjsFegsA%3D%3D
18. C. Addy S. Li N. Agrawal 2008 Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers J Clin Pharmacol 48 418 427 18258750 10.1177/0091270008314467 1:CAS:528:DC%2BD1cXkslKntL8%3D
19. C. Addy P. Rothenberg S. Li 2008 Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers J Clin Pharmacol 48 734 744 18508950 10.1177/0091270008317591 1:CAS:528:DC%2BD1cXns1Kit7Y%3D (Pubitemid 351713158)
20. Metropolitan height and weight tables. 1983, Stat Bull Metrop Life Found. 1983;64:3-9.
21. Mutnick AH. Digoxin. In: Schumacher GE, ed. Therapeutic Drug Monitoring. Norwalk, Connecticut: Appleton & Lange; 1995:469-491.
22. P.H. Hinderling D. Hartmann 1991 Pharmacokinetics of digoxin and main metabolites/ derivatives in healthy humans Ther Drug Monit 13 381 401 1957331 10.1097/00007691-199109000-00001 1:CAS:528:DyaK3MXms12qs74%3D